MedPath

CORTERIA PHARMACEUTICALS

CORTERIA PHARMACEUTICALS logo
🇫🇷France
Ownership
Holding
Established
2021-01-01
Employees
1
Market Cap
-
Website
http://www.corteriapharma.com

Clinical Trials

3

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

CRF2 Agonist for the Treatment of Worsening Heart Failure

Phase 2
Not yet recruiting
Conditions
Worsening Heart Failure
Interventions
Drug: Placebo
First Posted Date
2025-02-07
Last Posted Date
2025-02-11
Lead Sponsor
Corteria Pharmaceuticals
Target Recruit Count
300
Registration Number
NCT06815471

Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure

Completed
Conditions
Heart Failure
Heart Decompensation
First Posted Date
2023-02-28
Last Posted Date
2024-02-13
Lead Sponsor
Corteria Pharmaceuticals
Target Recruit Count
42
Registration Number
NCT05747820
Locations
🇦🇲

Institute of Cardiology Levon Hovhannisyan, Yerevan, Armenia

🇦🇲

Erebuni Medical Center, Yerevan, Armenia

🇧🇦

Health Institution Medico Laser, Cardiology ward, Banja Luka, Bosnia and Herzegovina

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.